- Belgian trial of Paris attack suspect postponed to February 5
- India's muted response to Trump's Jerusalem move stokes Arab unease
- Gunmen seize building in Afghan capital, firing on security forces
- How to buy and sell bitcoin - CNN Video
- Peru VP says committed to governing if president ousted
- Myanmar government says case against Reuters journalists can proceed
- Thomas Fire on course to become California's largest-ever wildfire
- Erdogan defies Trump, says Turkey has own embassy plans for Jerusalem
- Bitcoin futures trading just got a lot bigger
- Moscow says U.S. and North Korea should start a dialogue: RIA
- Australia's embattled Turnbull seen weighing cabinet reshuffle to expl
- At least 61 dead after days of violence in Ethiopia's Oromiya region
- Philippines says Maoist rebels attacked soldiers on typhoon relief dut
- U.S. taxpayers rush to claim deductions under threat from tax bill
- Tiny stem cell companies close in on major heart disease goals
- OAS says Honduran presidential election should be redone
- India ruling party pulls ahead in election in Modi state after tight r
- Atlanta's Hartsfield-Jackson airport restores power after crippling outage
- Mayor: Fire behind power outage; cause unknown - CNN Video
- Three Indian TV channels call Gujarat state polls in favor of PM Modi'
Roche says Tecentriq combination cuts lung cancer risk
ZURICH (Reuters) - A late-stage trial of Roche’s immuno-oncology medicine Tecentriq with other cancer drugs as an initial therapy for lung cancer met its goal of significantly reducing the risk of disease worsening or death, the Swiss drugmaker said on Monday.
With lung cancer easily the largest oncology market, Roche’s Impower 150 study of Tecentriq, Avastin and chemotherapy has been closely watched by investors and analysts as the company seeks to catch up with rival Merck in cancer immunotherapy.
Reporting by John Miller; Editing by Michael Shields
Our Standards:The Thomson Reuters Trust Principles.